Clinical Trial Update: Lutathera and ASTX727 in Neuroendocrine Tumours [Phase 1]

View source ↗

Summary

Imperial College London is conducting a Phase 1 study evaluating Lutathera in combination with ASTX727 for neuroendocrine tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Imperial College London | Conditions: Neuroendocrine Tumors | Phase 1 | Status: RECRUITING